Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

31,198 signal articles · 71 in last 24h · 159,848 total before filter · latest 46m ago
71last 24h
829last 7d
121● bullish (7d)
86● bearish (7d)
214publishers
AllMacro168Earnings201M&A86Regulatory18Product15Analyst26
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
Fiserv (FISV) Beats Q1 Earnings Estimates
Zacks149d agobullish
Fiserv (FISV) Beats Q1 Earnings Estimates

Fiserv (FISV) delivered earnings and revenue surprises of +13.67% and -1.72%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ON Semiconductor Beats Estimates but Shares Slip in Premarket Trading
InvestorsHub149d agobullish
ON Semiconductor Beats Estimates but Shares Slip in Premarket Trading

ON Semiconductor Corporation (NASDAQ:ON) reported quarterly results on Monday that exceeded expectations on both revenue and earnings, while also issuing stronger-than-forecast guidance for the current quarter. Despite this, the stock declined around 4% in premarket trading on Tuesday.

PayPal Stock Rises After Earnings. New CEO Is Off to a Good Start.
Barrons.com149d agobullish
PayPal Stock Rises After Earnings. New CEO Is Off to a Good Start.

Shares of PayPal rose Tuesday after the company reported better-than-expected quarterly earnings. The payments giant reported adjusted earnings of $1.34 a share for the first quarter, up from $1.33 a year ago and ahead of analysts’ consensus estimate of $1.27, per FactSet. PayPal stock jumped 3.1% in premarket trading.

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
Barrons.com149d agobullish
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.